Chinmay Trivedi

ORCID: 0000-0003-2545-9275
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Herpesvirus Infections and Treatments
  • Microscopic Colitis
  • Acne and Rosacea Treatments and Effects
  • Cytomegalovirus and herpesvirus research
  • Immunodeficiency and Autoimmune Disorders
  • Acute Lymphoblastic Leukemia research
  • Psoriasis: Treatment and Pathogenesis
  • Pharmaceutical studies and practices
  • Iron Metabolism and Disorders
  • Tuberculosis Research and Epidemiology
  • COVID-19 and healthcare impacts
  • Multiple Myeloma Research and Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Cutaneous Melanoma Detection and Management
  • COVID-19 Clinical Research Studies
  • Venous Thromboembolism Diagnosis and Management
  • Liver Diseases and Immunity
  • SARS-CoV-2 and COVID-19 Research
  • Pharmacological Effects of Natural Compounds
  • Gastrointestinal Tumor Research and Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Hemoglobinopathies and Related Disorders
  • Chronic Lymphocytic Leukemia Research
  • Nonmelanoma Skin Cancer Studies

Brown University
2025

Washington University in St. Louis
2025

Philadelphia VA Medical Center
2017-2024

Hackensack Meridian Health
2022-2024

Rhode Island Hospital
2024

Providence College
2024

University Gastroenterology
2021

James J. Peters VA Medical Center
2017

Icahn School of Medicine at Mount Sinai
2017

University of Pennsylvania
2017

Objective Our aim was to explore the risk of infection with all classes inflammatory bowel disease (IBD) medications and impact these on course in a nationwide cohort patients IBD. Design This retrospective national study IBD Veterans Affairs Healthcare System. We categorised medication use immediately prior COVID-19 pandemic used survival analysis methods associations SARS-CoV-2 infection, as well combined secondary outcome hospitalisation or COVID-19-related mortality. Results The...

10.1136/gutjnl-2021-324356 article EN cc-by-nc Gut 2021-03-22

To evaluate the role of albumin at time ulcerative colitis (UC) diagnosis in predicting clinical course disease.

10.3748/wjg.v23.i45.8008 article EN cc-by-nc World Journal of Gastroenterology 2017-12-04

The recent outbreak of the novel coronavirus disease 2019 (COVID-19) has become a pandemic and is threatening global health.1Wang C. et al.Lancet. 2020; 395: 470-473Abstract Full Text PDF PubMed Scopus (5092) Google Scholar highest number COVID-19 confirmed cases were reported in United States, with 1.47 million 89,272 deaths as May 19, 2020.2World Health Organization. Available at:...

10.1053/j.gastro.2020.05.065 article EN other-oa Gastroenterology 2020-05-29

Abstract Introduction: Pneumonitis is a serious and potentially lethal complication of treatment with immune checkpoint inhibitors (ICI). In rare subset patients, front-line steroids ineffective, necessitating second-line steroid-sparing agent. We conducted single-center, retrospective analysis patients treated ICIs to determine incidence outcome patterns who develop pneumonitis. Methods: manual chart review on cohort 2, 820 at our institution from 2015 2024. Steroid-refractory pneumonitis...

10.1158/1538-7445.am2025-5818 article EN Cancer Research 2025-04-21

There is a paucity of data on the clinical course and factors affecting herpes zoster (HZ) in inflammatory bowel disease (IBD). Our aim was to determine impact anti-TNF therapy other HZ IBD patients.We conducted retrospective cohort study among nation-wide Veterans Affairs patients with who developed incident HZ. The exposed group consisted eligible were actively alone or plus thiopurines at time onset. unexposed only 5-ASA agents before onset without any exposure medications. outcome...

10.1093/ibd/izx115 article EN public-domain Inflammatory Bowel Diseases 2018-03-07

INTRODUCTION: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are rare clonal disorders that commonly affect the elderly population have poor prognosis. There limited data on risk of AML/MDS among patients with inflammatory bowel disease (IBD), especially impact thiopurines (TPs). METHODS: We conducted a retrospective cohort study IBD from Veteran Affairs set. The exposure interest was TP exposure: (i) never exposed to TPs, (ii) past use (discontinued >6 months ago), (iii)...

10.14309/ajg.0000000000001058 article EN The American Journal of Gastroenterology 2020-11-26

Abstract Background The elderly inflammatory bowel disease (IBD) population has historically been under-represented in clinical trials, and data on the efficacy of biologic medications IBD patients are generally lacking. Our study aims to evaluate vedolizumab (VDZ) among compare it with younger a nationwide population-based cohort patients. Methods We conducted retrospective within US national Veterans Affairs Healthcare System (VAHS). Patients were stratified into 2 groups based age at time...

10.1093/ibd/izab163 article EN public-domain Inflammatory Bowel Diseases 2021-07-10

The risk of herpes zoster (HZ) is elevated in inflammatory bowel disease (IBD) patients treated with anti-TNF medications. While it optimal to give vaccine prior initiation therapy clinical circumstances may not always allow this.To determine the safety giving while are on therapy.We conducted a retrospective cohort study involving IBD who were followed Veterans Affairs (VA) healthcare system between 2001 and 2016. Patients received medication identified through vaccination codes confirmed...

10.1111/apt.14257 article EN Alimentary Pharmacology & Therapeutics 2017-08-14

Individuals with inflammatory bowel disease (IBD) have an increased risk of herpes zoster (HZ) infection. Although the efficacy recombinant vaccine (RZV) is high among immunocompetent individuals, little known about its effect immunosuppressed individuals IBD.We conducted a retrospective cohort study in national Veterans Affairs Healthcare System diagnosed IBD on or before January 3, 2018, earliest date RZV vaccinations. We collected data 7008 and 26,292 eligible patients 50- to 60-year...

10.1016/j.cgh.2021.07.023 article EN other-oa Clinical Gastroenterology and Hepatology 2021-07-15

Inflammatory bowel disease (IBD) patients are at an increased risk of herpes zoster (HZ). Our aim was to determine the frequency HZ vaccination and factors associated with it among eligible IBD patients. We conducted a retrospective cohort study who were followed in nationwide Veterans Affairs Healthcare system. Among this cohort, we identified age 60 years after introduction vaccination. The outcome interest for HZ. For all patients, follow-up began on January 1, 2008, ended incident...

10.1093/ibd/izy232 article EN public-domain Inflammatory Bowel Diseases 2018-07-05

Summary Background There are limited data on the incidence of pneumonia and pneumonia‐related hospitalisation in IBD population, any association medications with such outcomes. Aims To evaluate impact risk pneumonia, hospitalisations death. Methods We conducted a retrospective cohort study patients from nationwide Veteran Affairs (VA) dataset. The exposure interest was different medication groups. estimated rate mortality based subgroups. used multivariable Cox regression to estimate...

10.1111/apt.16610 article EN Alimentary Pharmacology & Therapeutics 2021-10-19

INTRODUCTION: There is paucity of data on the effectiveness and safety tofacitinib among elderly patients with ulcerative colitis (UC). METHODS: Through a retrospective cohort study US National Veterans Affairs Healthcare System, we evaluated (≥65) young (<65) UC initiated tofacitinib. RESULTS: Among 158 (53 elderly, 105 young), at 12 months was 50.94% in 33.33% ( P = 0.032). DISCUSSION: In nationwide initiating tofacitinib, seen half patients.

10.14309/ajg.0000000000002761 article EN cc-by-nc-nd The American Journal of Gastroenterology 2024-03-14

Although the prevalence of anemia has been extensively studied in inflammatory bowel disease (IBD) population, no study evaluated duration time IBD patients remain anemic over course their disease. Our aims were to determine incidence, anemia, and rate receipt iron therapy among compare these with non-IBD patients. We conducted a retrospective nationwide cohort US veteran population from January 2011 September 2018. Inflammatory who not at first medication included matched estimated...

10.1093/ibd/izz206 article EN public-domain Inflammatory Bowel Diseases 2019-09-27

Ornithine transcarbamylase (OTC) is a mitochondrial-matrix enzyme that catalyzes conversion of ornithine and carbamyl phosphate to citrulline, the second step in urea cycle. The cycle most important pathway detoxification ammonia human beings. deficiency (OTCD) common disorder, inherited as an X-linked disorder can cause fatal hyperammonemia male newborns. Women with OTCD have variable expression their disease, variability being determined by lyonization (random inactivation) X chromosome....

10.1097/00004836-200104000-00013 article EN Journal of Clinical Gastroenterology 2001-04-01

Primary sclerosing cholangitis (PSC) is commonly associated with ulcerative colitis (UC). Our aim was to compare the course of disease in patients UC-PSC and UC alone a nationwide cohort. We conducted retrospective cohort study among nation-wide Veterans Affairs (VA) newly diagnosed determine association between PSC status clinical outcomes related course. This divided into 2 groups patients: (1) The incident group (2) UC-alone group. Follow-up began at time index colonoscopy that ended...

10.1093/ibd/izy106 article EN public-domain Inflammatory Bowel Diseases 2018-04-25

INTRODUCTION: There are limited data on repeated basal cell cancer (BCC) occurrences among patients with inflammatory bowel disease (IBD), especially the impact of continuing immunosuppressive medications. METHODS: We conducted a retrospective cohort study 54,919 IBD followed in Veterans Affairs Healthcare System. identified who had an incident BCC after their diagnosis. defined patients' exposure based medications use as follows: (i) only aminosalicylate (5-ASA) use, (ii) active thiopurine...

10.14309/ajg.0000000000000679 article EN The American Journal of Gastroenterology 2020-05-22

Data on safety and efficacy of switching to Renflexis (SB2) from originator Infliximab (IFX) (single switch) or IFX Inflectra (CT-P13) (double are limited.We conducted a retrospective cohort study in nationwide patient with inflammatory bowel disease (IBD) remission who were switched SB2. The main exposure was the treatment course There 2 levels this variable: single switch (IFX SB2) double CT-P13 SB2). outcome is SB2 drug discontinuation rate and/or not being after 1 year. Logistic...

10.1093/crocol/otab022 article EN cc-by-nc Crohn s & Colitis 360 2021-03-19
Coming Soon ...